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Human transposable element (TE) activity in somatic tissues causes mutations that can
contribute to tumorigenesis. Indeed, TE insertion mutations have been implicated in the
etiology of a number of different cancer types. Nevertheless, the full extent of somatic TE
activity, along with its relationship to tumorigenesis, have yet to be fully explored. Recent
developments in bioinformatics software make it possible to analyze TE expression levels
and TE insertional activity directly from transcriptome (RNA-seq) and whole genome
(DNA-seq) next-generation sequence data. We applied these new sequence analysis
techniques to matched normal and primary tumor patient samples from the Cancer
Genome Atlas (TCGA) in order to analyze the patterns of TE expression and insertion for
three cancer types: breast invasive carcinoma, head and neck squamous cell carcinoma,
and lung adenocarcinoma. Our analysis focused on the three most abundant families of
active human TEs: Alu, SVA, and L1. We found evidence for high levels of somatic TE
activity for these three families in normal and cancer samples across diverse tissue types.
Abundant transcripts for all three TE families were detected in both normal and cancer
tissues along with an average of ∼80 unique TE insertions per individual patient/tissue.
We observed an increase in L1 transcript expression and L1 insertional activity in primary
tumor samples for all three cancer types. Tumor-specific TE insertions are enriched for
private mutations, consistent with a potentially causal role in tumorigenesis. We used
genome feature analysis to investigate two specific cases of putative cancer-causing
TE mutations in further detail. An Alu insertion in an upstream enhancer of the CBL
tumor suppressor gene is associated with down-regulation of the gene in a single breast
cancer patient, and an L1 insertion in the first exon of the BAALC gene also disrupts its
expression in head and neck squamous cell carcinoma. Our results are consistent with
widespread somatic activity of human TEs leading to numerous insertion mutations that
can contribute to tumorigenesis in a variety of tissues.
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INTRODUCTION
More than 50% of the human genome sequence is derived from transposable element (TE)
insertions (Lander et al., 2001; de Koning et al., 2011). The vast majority of TE-derived sequences
in the human genome correspond to relatively ancient insertions that are no longer capable of
transposition (Mills et al., 2007). However, there are several families of human TEs that remain
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active to this day. The most abundant families of active TEs
in the human genome are the Alu and SVA short interspersed
nuclear elements (SINEs) along with the L1 Long Interspersed
Nuclear Element (LINE) family (Kazazian et al., 1988; Batzer
and Deininger, 1991; Batzer et al., 1991; Brouha et al., 2003;
Ostertag et al., 2003; Wang et al., 2005). Alu and SVA SINEs are
non-autonomous TEs that are mobilized via the transpositional
machinery encoded by the autonomous L1 family of LINEs.
Recent evidence indicates that a handful of HERV-K endogenous
retroviral elements also remain active in the human genome
(Wildschutte et al., 2016).
Active TE families are of great interest since they have the
ability to generate de novo mutations, many of which have
been linked to human disease (Hancks and Kazazian, 2012;
Solyom and and Kazazian, 2012). For instance, TE insertions
have been shown to contribute to the etiology of a variety of
different cancer types (Belancio et al., 2010a; Carreira et al.,
2014). Numerous recent studies have used a combination of next-
generation sequence analysis, followed by validation with PCR
and/or Sanger sequencing, to elucidate connections between TE
activity and cancer (Solyom et al., 2012; Shukla et al., 2013; Tubio
et al., 2014; Doucet-O’Hare et al., 2015; Ewing et al., 2015). L1
insertions in particular have been implicated as potential cancer
causing mutations in those and other studies (Morse et al., 1988;
Miki et al., 1992; Iskow et al., 2010; Lee et al., 2012; Scott et al.,
2016). L1 activity is thought to promote tumor development by
causing genomic instability, via impaired chromosomal pairing
during mitosis, and/or by disrupting coding or regulatory
sequences (Kemp and Longworth, 2015).
Many of the studies that have related TEs to cancer have
considered TE expression, at the transcript or protein level, and
TE insertional activity separately. A number of different cancer
types are positive for L1 transcript expression (Belancio et al.,
2010b), and L1 proteins have been shown to be ubiquitously
expressed in both normal and tumor samples from the same
individuals (Bratthauer and Fanning, 1992, 1993; Bratthauer
et al., 1994; Asch et al., 1996; Doucet-O’Hare et al., 2015, 2016).
There is also evidence suggesting that L1 protein expression
can be limited to tumor tissues and thereby serve as a useful
cancer biomarker; nearly half of all human cancers are exclusively
immunoreactive for L1-ORF1 encoded proteins (Rodic et al.,
2014). The expression of L1 proteins in tumors has been
shown to affect the expression of a number of cancer-related
genes, including the down-regulation of tumor suppressors
(Rangasamy et al., 2015). With respect to TE insertional activity,
studies on matched normal and tumor tissues have found that
novel L1 insertions occur at high frequencies in lung cancer
genomes (Iskow et al., 2010). Such insertions frequently occur
in oncogenes and tumor suppressors, underscoring their putative
role in tumorigenesis (Lee et al., 2012).
A principal challenge when interpreting cancer genomes is
distinguishing between so-called passenger and driver mutations.
While passenger mutations are present in cancer genomes,
they are not considered to contribute to cancer progression;
instead, they are simply somatic mutations that arise during
carcinogenesis and are carried along during clonal expansion.
Driver mutations, on the other hand, are causal mutations that
are directly implicated in carcinogenesis and the promotion
of cancer growth (Stratton et al., 2009; Marx, 2014; Pon and
Marra, 2015). To date, only a few studies have directly implicated
TE insertions as cancer driver mutations. One such study
analyzed 19 hepatocellular carcinoma genomes utilizing the RC-
Seqmethodology (Baillie et al., 2011) and discovered two separate
L1 insertions that initiate tumorigenesis via distinct oncogenic
pathways (Shukla et al., 2013). This study found L1 insertions
in two different tumor suppressor genes: Mutated in Colorectal
Cancers (MCC) and Suppression of Tumorigenicity (ST18).
Most recently, a role for L1 insertional activity was conclusively
demonstrated for colorectal cancer caused by an insertion in
the APC tumor suppressor gene (Scott et al., 2016). This paper
describes a somatic L1 insertion into one copy of the APC gene
that, when coupled with a point mutation in the other copy of
the gene, initiates tumorigenesis through the two hit colorectal
cancer pathway.
Owing to parallel developments in genomics and
bioinformatics, it is now possible to jointly analyze the patterns
of TE transcript expression and TE insertional activity in human
cancers. The Cancer Genome Atlas (TCGA) provides access to
both transcriptome sequence data (RNA-seq) and whole genome
sequence data (DNA-seq) for a number of matched normal and
primary tumor sample pairs from individual patients (Weinstein
et al., 2013). In addition, recently developed bioinformatics
algorithms allow for the detection of TE transcripts directly from
RNA-seq data (Jin et al., 2015) as well as for the characterization
of novel TE insertions from DNA-seq data (Thung et al.,
2014; Sudmant et al., 2015). We took advantage of these
developments in order to evaluate the patterns of both TE
expression and insertional activity in three cancer types: breast
invasive carcinoma, head, and neck squamous cell carcinoma,
and lung adenocarcinoma (Figure 1 and Supplementary Figure
1). We observed a simultaneous increase of L1 transcript
expression and L1 insertional activity for primary tumor samples
for all three cancers, and we evaluate individual cases of TE
insertions that are implicated as potential cancer causing
mutations.
MATERIALS AND METHODS
Genome and Transcriptome Sequence
Data
Whole genome sequence data (DNA-seq), transcriptome
sequence data (RNA-seq) and patient metadata for matched
normal and primary tumor tissue samples from nine cancer
patients were acquired from The TCGA (Weinstein et al., 2013)
via the Cancer Genomics Hub (CGHub) using the download
client GeneTorrent (Maltbie et al., 2013). The nine participants
included three breast invasive carcinoma patients, three head
and neck squamous cell carcinoma patients and three lung
adenocarcinoma patients (Table 1). DNA-seq and RNA-seq data
were accessed as BAM files of paired-end Illumina sequence data
aligned against the human genome reference sequence (build
hg19). BAM files containing sequence alignments were validated
for quality using FASTQC (Andrews, 2011), and autosomes were
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FIGURE 1 | Scheme of the analytical design used in this study. Matched
normal and primary tumor samples for three cancer types were analyzed using
transcriptome (RNA-seq) and whole genome (DNA-seq) data. RNA-seq data
was analyzed to compare normal versus cancer expression levels, and
DNA-seq data was analyzed to identify somatic TE insertion events. The main
bioinformatics programs (wrench) and databases (cylinder) used for each
phase of the analysis are indicated.
extracted from the BAM files for downstream analysis using
SAMtools (Li et al., 2009).
Gene and Transposable Element (TE)
Expression Levels
Gene and TE expression levels were measured using RNA-seq
data for the nine matched normal and primary tumor tissue
samples. Gene expression levels were quantified as read counts
mapped to NCBI RefSeq gene annotations (Pruitt et al., 2012).
TE expression levels—for Alu, L1 and SVA elements—were
quantified using reads mapped to RepeatMasker annotations,
which were subsequently analyzed with the TEtranscripts
package (Jin et al., 2015). The TEtranscripts program uses an
expectation maximization (EM) algorithm to choose optimal
unique TE locations for multi-mapped reads, thereby allowing
for accurate expression level measurements for active TE
families. The TEtranscripts method was recently shown to yield
more reliable measures of TE transcription levels compared to
previously published methods, such as HTSeq-count, Cuﬄinks,
and RepEnrich (Trapnell et al., 2010; Criscione et al., 2014;
Anders et al., 2015). The L1Base database was used to identify
the genomic locations of 145 full length, intact elements from
the most recently active L1 subfamily (Penzkofer et al., 2005).
The set of full-length intact L1 sequences from the L1Base was
generated by performing a BLAST search using the human
genomic DNA sequences against the L1 template sequence
(Penzkofer et al., 2005). L1Base was used to facilitate measures
of active L1 element expression by limiting our analysis to RNA-
seq reads that map to full-length, intact L1 sequences which
retain the potential to be transpositionally active. This was
done in an effort to ensure that the reads we analyzed were
taken from potentially active L1 elements as opposed to older
fixed elements, which could represent read-through transcripts
initiated from nearby genomic promoters. The expression levels
of these potentially active L1 elements were analyzed separately
using the TEtranscripts method.
Differential expression levels between normal and cancer
tissue pairs, for genes and TEs, were evaluated by comparing
distributions of log10 transformed RNA-seq expression levels
characterized as described above. The statistical significance
levels of the observed differential expression between normal and
cancer pairs were evaluated by comparing these distributions
using the non-parametric Kolmogorov-Smirnov test. Statistical
comparisons were done separately for each tissue (cancer)
type: breast invasive carcinoma, head and neck squamous cell
carcinoma and lung adenocarcinoma.
Transposable Element Insertion Detection
The genomic locations of novel TE insertions from matched
normal and primary tumor tissue samples were predicted based
on discordant read-pair mapping of DNA-seq data (Ewing,
2015) (Table 2). A scheme of our TE insertion detection analysis
pipeline is shown in Supplementary Figure 2. DNA-seq BAMfiles
were realigned according to GATK’s standard indel realignment
method (Van der Auwera et al., 2013) to facilitate TE insertion
detection. The programs MELT (Sudmant et al., 2015) and
Mobster (Thung et al., 2014) were used together for TE insertion
detection. These two programs were selected owing to their
previously demonstrated superior performance for human TE
insertion detection (Rishishwar et al., 2016). Only TE insertion
sites that were found by both methods (i.e., the intersection of
the predictions) were used for subsequent analysis. TE insertion
predictions made by the individual programs were considered
to represent the same insertion if they were found within
±100 bp of each other. An additional filtering step was applied
based on the number of mapped sequence reads (coverage) that
support each TE insertion prediction. Only predictions with
a minimum coverage of 5 reads and a maximum coverage of
4X the average sequencing depth of the sample were used for
subsequent analysis. These upper and lower cut-off thresholds
were empirically chosen based on the observed distributions
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TABLE 1 | TCGA whole genome (DNA-seq) and transcriptome (RNA-seq) data sources for the patients analyzed in this study.
ID TCGA barcode Cancer type Sex Age Sample typea Seq depth Read len.
Breast 1 TCGA-BH-A0B3-11B-21D-A128-09 Breast invasive carcinoma F 53 NT-W 42.4 100
TCGA-BH-A0B3-11B-21R-A089-07 NT-R 5.5 50
TCGA-BH-A0B3-01A-11D-A128-09 TP-W 40.2 100
TCGA-BH-A0B3-01B-21R-A089-07 TP-R 5.4 50
Breast 2 TCGA-BH-A0BW-11A-12D-A314-09 F 71 NT-W 54.1 100
TCGA-BH-A0BW-11A-12R-A115-07 NT-R 7 50
TCGA-BH-A0BW-01A-11D-A10Y-09 TP-W 46.1 100
TCGA-BH-A0BW-01A-12R-A115-07 TP-R 7.3 50
Breast 3 TCGA-BH-A0DT-11A-12D-A12B-09 F 41 NT-W 63.3 100
TCGA-BH-A0DT-11A-12R-A12D-07 NT-R 7.7 50
TCGA-BH-A0DT-01A-21D-A12B-09 TP-W 79.9 100
TCGA-BH-A0DT-01A-21R-A12D-07 TP-R 6.6 50
Head 1 TCGA-CV-7255-11A-01D-2276-10 Head and neck squamous cell carcinoma F 32 NT-W 6.9 101
TCGA-CV-7255-11A-01R-2016-07 NT-R 7.5 48
TCGA-CV-7255-01A-11D-2276-10 TP-W 5.8 101
TCGA-CV-7255-01A-11R-2016-07 TP-R 7.1 48
Head 2 TCGA-CV-7416-11A-01D-2334-08 F 29 NT-W 7.7 101
TCGA-CV-7416-11A-01R-2081-07 NT-R 5.9 48
TCGA-CV-7416-01A-11D-2334-08 TP-W 28.6 101
TCGA-CV-7416-01A-11R-2081-07 TP-R 6 48
Head 3 TCGA-CV-6959-11A-01D-1911-02 M 48 NT-W 38.3 51
TCGA-CV-6959-11A-01R-1915-07 NT-R 8.5 48
TCGA-CV-6959-01A-11D-1911-02 TP-W 31.4 51
TCGA-CV-6959-01A-11R-1915-07 TP-R 6.6 48
Lung 1 TCGA-44-6776-11A-01D-1853-02 Lung adenocarcinoma F 60 NT-W 38.9 51
TCGA-44-6776-11A-01R-1858-07 NT-R 5.4 48
TCGA-44-6776-01A-11D-1853-02 TP-W 6.9 51
TCGA-44-6776-01A-11R-1858-07 TP-R 7.4 48
Lung 2 TCGA-50-5932-11A-01D-1753-08 M 75 NT-W 34.6 101
TCGA-50-5932-11A-01R-1755-07 NT-R 4.2 48
TCGA-50-5932-01A-11D-1753-08 TP-W 44.5 101
TCGA-50-5932-01A-11R-1755-07 TP-R 7.4 48
Lung 3 TCGA-55-6984-11A-01D-1945-08 F NA NT-W 36.2 101
TCGA-55-6984-11A-01R-1949-07 NT-R 4.9 48
TCGA-55-6984-01A-11D-1945-08 TP-W 41 101
TCGA-55-6984-01A-11R-1949-07 TP-R 5.2 48
aNT-D, Normal tissue DNA-seq; NT-R, Normal tissue RNA-seq; TP-D, Tumor primary DNA-seq; TP-R, Tumor primary RNA-seq.
of the numbers of discordant mapped read pairs used to
call individual TE insertions. Read count distributions were
computed individually for each program (MELT, Mobster) used
and for each sample (Supplementary Figure 3). The resulting
distributions were typically bimodal with a lower peak (i.e., with
lower read count support) that we considered to be enriched
for potential false positive TE insertion calls. The lower cut-off
threshold of 5 reads was chosen to minimize such false positives,
and the upper cut-off threshold was chosen to remove calls
made in genomic regions that show anomalously high numbers
of mapped reads, which tend to be enriched for ambiguously
mapped reads.
The number of observed versus expected counts of unique
L1 insertions were compared for matched normal and primary
tumor tissue samples. The observed counts were taken from the
TE detection pipeline, and the expected counts were computed
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TABLE 2 | Numbers of MELT and Mobster predicted TE insertions in matched normal (N) and primary tumor (T) samples across 9 individuals.
Participant ID TE insertions in matched normal tissue TE insertions in tumor primary tissue
Alu SVA L1 Total Alu SVA L1 Total
Breast 1 913 28 127 1069 853 33 110 997
Breast 2 1004 21 121 1147 1160 54 143 1358
Breast 3 1012 63 139 1215 952 60 136 149
Head 1 984 72 140 1197 741 66 107 915
Head 2 945 25 131 1102 832 26 138 997
Head 3 860 36 108 1005 819 41 112 973
Lung 1 716 29 92 838 780 36 113 930
Lung 2 806 25 103 935 701 20 94 816
Lung 3 856 21 110 988 746 14 100 861
as the ratio of unique insertions seen in matched normal vs.
primary tissue for all TEs multiplied by the total number of
observed L1 insertions. The significance of the difference between
the observed versus expected counts of unique L1 insertions was
evaluated using the Fisher’s exact test. Counts of TE insertions
for matched normal and primary tumor tissue samples were
characterized based on their frequencies from the 1000 Genomes
Project (1KGP) (Sudmant et al., 2015) and grouped into three
distinct frequency bins. The distributions of TE insertion counts
across the three frequency bins were compared for matched
normal and cancer samples for the different tissue types analyzed
here, and the significance of the differences between these
distributions were evaluated using the Kolmogorov-Smirnov test.
TE Insertion Genome Feature Analysis
The genomic locations of novel TE insertions were considered
with respect to several genomic features using the BEDTools
program (Quinlan, 2014): RefSeq genes (Pruitt et al., 2012),
COSMIC tumor suppressor genes (Forbes et al., 2015), and
enhancer elements defined by chromatin states (Roadmap
Epigenomics et al., 2015). The population allele frequencies of
the predicted TE insertions were computed from the Phase 3
release of the 1KGP (Sudmant et al., 2015) as previously described
(Rishishwar et al., 2015).
RESULTS AND DISCUSSION
TE Expression Levels in Matched Normal
vs. Primary Tumor Tissue Samples
RNA-seq data were used to evaluate the differences in TE
expression levels between matched normal and primary tumor
tissue samples as described in the Materials and Methods.
The observed differences in gene expression levels between
normal and tumor tissue were compared to differences in TE
expression levels for breast invasive carcinoma, head, and neck
squamous cell carcinoma and lung adenocarcinoma. There are
no significant differences observed for the distributions of gene
expression levels between matched normal and primary tumor
tissue pairs for any of the three cancer types analyzed here
(Figure 2). Similarly, when all three families of potentially active
TEs (Alu, L1, and SVA) are considered together, there is no
significant difference seen for the overall levels of expression
between matched normal and tumor tissue. However, when full-
length, potentially active L1 sequences are considered alone, we
observe statistically significant increases in L1 expression levels
for all three cancer types.
The methods that we used to characterize TE expression levels
include several analytical controls aimed to ensure that only
genuine TE-initiated transcripts, from members of potentially
active families, are measured. Nevertheless, the lack of a
difference between normal and tumor expression levels observed
when all three active TE families were considered together
could reflect technical difficulties with identifying bona fide TE
transcripts that are initiated from element promoters as opposed
to TE sequences that are passively expressed as part of longer
genic transcripts. This is particularly true for Alu elements,
many of which are found in the introns of human genes and
transcribed as read-through transcripts initiated from RNA Pol
II gene promoters (Deininger, 2011). Our confidence in the
ability to measure L1-initiated transcripts is higher owing to the
focus on previously identified full-length, intact elements that
are located in intergenic regions. In any case, the up-regulation
of L1s in cancer that we observed has potential implications for
increased TE insertional activity for all three families, since L1
encoded proteins are responsible for the cis retrotransposition
of L1s as well as the trans activation of Alu and SVA elements
(Batzer and Deininger, 2002; Hancks and Kazazian, 2010). We
analyzed the same pairs of matched normal and primary tumor
tissues to evaluate whether the observed increase in L1 expression
corresponds to increased transpositional activity of human TEs.
Novel TE Insertions in Matched Normal
and Primary Tumor Tissue Samples
It is now possible to characterize the genomic locations and
copy numbers of individual TE insertions from whole genome
DNA-seq data owing to recent developments in computational
genomics software (Ewing, 2015; Rishishwar et al., 2016). This
technological advance is exemplified by the recent Phase 3 release
of the 1KGP, which includes a complete genome-wide census
of polymorphic TE insertion sites for 2504 individuals across
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FIGURE 2 | Gene expression levels for matched normal vs. primary tumor tissue pairs. Normal tissue (NT) and tumor primary (TP) expression levels were
measured for genes, transposable elements (TEs) and LINE1 elements (L1s) via analysis of RNA-seq data as described in the Materials and Methods. Expression
levels are shown as distributions of log10 transformed read counts, and normal versus tumor comparisons are shown for breast invasive carcinoma (green), head and
neck squamous cell carcinoma (red), and lung adenocarcinoma (blue). For each tissue type, the significance levels of the differences in L1 expression between normal
and cancer pairs are indicated with P-values from the Kolmogorov-Smirnov test.
26 human populations (Sudmant et al., 2015). We analyzed
whole genome DNA-seq data using computational methods for
TE insertion detection (see Materials and Methods) in order to
compare TE insertional activity between matched normal versus
primary tumor tissue samples.
When all three families of active human TEs are considered
together, we observed a total of 3672 TE insertions across
the nine individuals analyzed for normal and cancer tissue
pairs, 693 of which are unique insertions found in only one
individual and one tissue type. In other words, we observe
an average of ∼77 unique somatic TE insertions per person,
i.e., “private” TE insertions. This estimate is similar to the
value of ∼90 unique (presumably germline) TE insertions
that we previously observed for individuals from the 1KGP
(Rishishwar et al., 2015). A large majority of the observed
TE insertions—81% for all TEs and 62% for L1s alone—
are shared between the normal and tumor tissue types of an
individual, suggesting that they represent germline insertions
(Figure 3A). There are 1.3x more unique TE insertions seen
for tumor compared to normal tissue, and this effect is more
pronounced for L1s alone, which are 2x more abundant in tumor
tissue samples. Accordingly, there is a statistically significant
excess of observed versus expected L1 insertions in tumor
versus normal tissue (P = 0.019) (Figure 3B). These results are
consistent with a potential role for L1 transpositional activity
in tumorigenesis for the cancer types analyzed here, as has
been previously suggested for several different cancers (Morse
et al., 1988; Iskow et al., 2010; Lee et al., 2012; Scott et al.,
2016).
Given the relatively high level of L1 insertional activity in the
tumor tissue samples analyzed here, we tested whether tumor-
specific L1 insertions are found at lower frequencies among
the (presumably) healthy donors from the 1KGP compared
to L1 insertions found in matched normal tissue. The idea
was to evaluate whether the tumor-specific L1 insertions
represent mutations that are private, and thereby more likely
to be deleterious or disease-causing. To do this, individual
TE insertions were classified as high frequency (>0.05), low
frequency (<0.05) or private (absent) according to their
previously characterized population (allele) frequencies from the
1KGP (Rishishwar et al., 2015; Sudmant et al., 2015).
When all three cancer types are considered together, there
is a statistically significant excess of private and low frequency
TE insertions observed for tumor compared to normal tissue (P
= 1.9e-61) (Figure 3C). This effect is even more pronounced
when L1 insertions are considered alone (P = 2.7e-23). The
same pattern of an increased frequency of private L1 insertions
in tumor tissue is observed (P < 2.0e-7) when all three cancer
types are analyzed for sets of patients (Figures 3D–F) and
when samples for individual patients are analyzed separately
(Supplementary Figure 4). The strongest effect is seen for head
and neck squamous cell carcinoma. The pattern of a significant
excess of private L1 insertions in tumor compared to normal
tissue, observed for all three cancer types studied here, provides
further evidence in support of a possible role for L1 activity in
tumorigenesis.
It should be noted TE insertions found in low copy numbers
may not be detectable using next-generation sequence analysis,
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FIGURE 3 | TE insertional activity in matched normal vs. primary tumor tissue pairs. The number of TE insertions were measured for normal and primary
tumor tissue pairs for breast invasive carcinoma, head, and neck squamous cell carcinoma and lung adenocarcinoma via analysis of whole genome DNA-seq data as
described in the Materials and Methods. (A) The total number of predicted TE insertions, pooled for all nine individuals over the three cancer types analyzed here, are
shown for normal vs. tumor tissue. Venn diagrams show the numbers of unique versus shared TE insertions for the two tissue types. (B) Comparison of the observed
versus expected numbers of unique L1 insertions for normal vs. tumor tissue. (C) Comparison of the population frequencies of observed TE insertions in matched
normal vs. tumor tissue pairs are shown for all of the TEs analyzed here and for L1s alone. (D–F) The same comparisons of TE insertion population frequencies are
shown individually for each cancer type analyzed here. TE insertion population frequencies are color coded as shown in the key. P-values show the significance of the
differences for observed distributions based on the Fisher’s exact test (B) and the Kolmogorov-Smirnov test (C–F).
whereas such insertions may be uncovered using more sensitive
PCR-based approaches. False negatives of this kind will be more
prevalent at low levels of sequence coverage. We have tried
to control for this by using relatively high sequence coverage
(∼35X) studies here, but the conservative lower read count
cut-off of 5 reads per TE insertion call that we used may still lead
tomissing TE insertion calls. Sequence based predictions can also
yield false-positive TE insertion calls. In an effort to deal with
this issue, we have only used high-confidence calls produced by
two independent programs—MELT and Mobster—that we have
recently shown to be most reliable for the detection of human TE
insertions (Rishishwar et al., 2016).
One other potential problem with the sequence based analysis
relates to the base pair resolution with which TE insertions can
be called via computational analysis of next-generation sequence
data. Currently, the most accurate programs for calling TE
insertions from next-generation sequence data do not yet allow
for the insertions to be precisely located to genomic regions
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FIGURE 4 | Private TE insertions implicated as potential cancer driver mutations. (A) A tumor-specific Alu insertion (red) is found in a single breast cancer
patient. The insertion is located within an upstream enhancer for the CBL gene on chromosome 11 (gene model shown in blue), as indicated by enhancer-associated
chromatin marks (inset yellow bars). Presence of the Alu insertion is associated with down-regulation of CBL (expression levels in green). (B) A tumor-specific L1
insertion (red) is located within the first exon of the BAALC gene on chromosome 8 (gene model shown in blue). Co-location of the L1 insertion with
promoter-associated chromatin marks (purple bars) is shown in the inset. Presence of the L1 insertion is associated with down-regulation of BAALC (expression levels
in red).
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at single base pair resolution. To account for this fact, TE
insertions called within a window of ±100 bp are considered
to be co-located (Supplementary Figure 2). It is possible that
this approximation can lead to multiple TE insertion events
being collapsed into a single event. Subsequent experimental
confirmation of individual TE insertion calls of interest (e.g.,
potentially tumorigenic TE insertions) should help to provide
certainty with respect to both their validity and their precise
genomic locations.
Potentially Tumorigenic TE Insertions
Having established a potential role for transpositional activity
in tumorigenesis using the genome-wide approaches described
above, we wanted to search for specific examples where individual
TE insertions could be implicated as possible cancer driver
mutations. To do so, we performed an integrated analysis of TE
insertion, gene expression and chromatin data (see Materials and
Methods) in an effort to identify the cancer-specific TE insertions
that are most likely to play a causal role in tumorigenesis.
We considered TE insertions that are co-located with either
exons or regulatory elements of previously characterized tumor
suppressor genes to have the highest likelihood of being
functionally relevant. We observed a total of 141 intragenic
(35.9%) insertions and 246 intronic insertions (62.6%) out of the
393 total cancer-specific insertions in our dataset. None of these
intergenic or intronic cancer-specific TE insertions were found
to disrupt any known functional (regulatory) sequence element.
Thus, consistent with previous studies, the vast majority of TE
insertions that we observed are not likely to affect gene function
or expression in cancer. We did find 4 exonic TE insertions,
along with 2 insertions located in regulatory elements, for known
tumor suppressor genes (1.5% of the total). Here, we focus on
two of these potential cases of cancer driver TE insertions, which
could prove to be of interest to the TE and/or cancer research
communities.
There is a private, breast cancer tumor-specific Alu insertion
that is located within an upstream enhancer element that helps
to regulate the expression of the Cbl Proto-Oncogene (CBL) gene
(Figure 4A). CBL is classified as a tumor suppressor gene by the
COSMIC database (Forbes et al., 2015). It has been found to
be mutated or translocated in a number of cancers including
acute myeloid leukemia (Abbas et al., 2008; Naramura et al.,
2011; Aranaz et al., 2013); mutations in CBL are also the cause
of Noonan syndrome-like disorder (Martinelli et al., 2010). The
CBL encoded protein functions as a negative regulator of signal
transduction pathways (Schmidt and Dikic, 2005), activation of
which have been associated with cancer (Sever and Brugge, 2015).
The tumor-specific Alu enhancer insertion that we characterized
is associated with down-regulation of CBL expression, consistent
with a potential role in tumorigenesis via the activation of signal
transduction pathways associated with cell proliferation (Sever
and Brugge, 2015).
We also found a private L1 insertion that was unique
to a head and neck squamous cell carcinoma tissue sample,
located within the first exon of the Brain and Acute Leukemia,
Cytoplasmic (BAALC) gene (Figure 4B). As its name implies, the
BAALC gene is expressed in the brain and related neural tissues,
and it was first identified by association with acute myeloid
leukemia where it was shown to be overexpressed (Damiani
et al., 2013; Zhou et al., 2015). TE insertions within exons are
extremely rare and would presumably have a dramatic effect
on gene function. Indeed, this particular insertion is associated
with nearly complete inactivation of the BAALC gene. This
is consistent with previous results showing that the presence
of fixed L1 insertions genome-wide is strongly associated with
the down-regulation of human gene expression (Han et al.,
2004). A recent study has demonstrated that BAALC can inhibit
extracellular signal-regulated kinase (ERK) mediated monocytic
differentiation of AML cells (Morita et al., 2015). Thus, down-
regulation of BAALC would presumably result in a loss of
control over cellular differentiation, consistent with a possible
role in tumorigenesis. A recent study discovered a role for the
change in methylation status of a cancer-specific L1 insertion
in tumorigenesis (Scott et al., 2016); this could be an additional
mechanism by which the BAALC L1 insertion observed here
exerts a regulatory effect.
CONCLUSION
The results of our analysis show a surprisingly high level of
somatic TE activity in the human genome. Abundant transcripts
from members of all three active human TE families analyzed
here—Alu, SVA and L1—can be identified for both normal
and cancer tissue samples. In addition, after filtering for high
confidence TE insertion calls, we identified an average of close to
80 unique insertions for each tissue among the individual patients
in our study. Thus, active human TE families retain the ability to
transpose in somatic tissue thereby generating substantial levels
of cellular heterogeneity among diverse tissues.
We also observe a correlated increase in both transcript
expression levels and transpositional activity for L1 elements
in cancer tissue samples when compared to matched normal
tissue. Increased cancer expression of L1 elements is particularly
relevant for TE insertional activity, since the L1 transpositional
machinery is responsible for transposing non-autonomous Alu
and SVA elements in trans along with L1 elements in cis. Our
results are consistent with previous studies showing expression
of L1 transcripts in lung cancer (Belancio et al., 2010b) and
expression of L1 ORF1p in breast cancer (Harris et al., 2010),
and tumor-specific L1 insertions have also previously been found
in breast (Morse et al., 1988), head and neck (Helman et al.,
2014), and lung tumors (Helman et al., 2014). We confirmed
the presence of numerous tumor-specific L1 insertions in these
three cancer types and identify two potentially tumorigenic TE
insertions, an Alu insertion in the enhancer region of the tumor
suppressor gene CBL and an L1 insertion in the first exon of the
BAALC gene. These results underscore the potential for somatic
TE activity to generate cellular heterogeneity and to contribute to
the etiology of cancer across a wide range of human tissues.
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